ENBREL(R) SureClick(TM) receives Arthritis Friendly Commendation
from The Arthritis Society
MONTREAL, April 4 /CNW Telbec/ - Canadians with rheumatoid arthritis and
psoriasis now have an innovative new delivery option, which makes it simpler
and more convenient for patients to self-administer ENBREL(R), with the push
of a button. Now available in pharmacies across Canada, ENBREL SureClick(TM)
is the first prefilled autoinjector indicated for people who are affected by
rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis,
plaque psoriasis and ankylosing spondylitis.
"For many of my patients with rheumatoid arthritis, self-injecting a
biologic treatment can be a challenge, particularly for those who are afraid
of needles or who have significant hand discomfort," says Dr. Paul Haraoui,
Associate Professor of Medicine, University of Montreal Director of Clinical
Research, Rheumatic Disease Unit, CHUM. "ENBREL SureClick is easy to use and
convenient, which will simplify self-administration."
ENBREL SureClick autoinjector, which comes prefilled with a single
50 mg/mL dose of ENBREL, has received an Arthritis Friendly Commendation from
The Arthritis Society for its simple and easy-to-use design. The needle for
ENBREL SureClick is hidden throughout the injection. Patients also benefit
from the following features:
- A safety needle cover that unlocks when the autoinjector is placed
firmly against the injection site.
- Two "audible" clicks to announce the beginning and end of the
- A large inspection window shows the full dose has been delivered.
"It is reassuring that companies like Amgen Canada and Wyeth Canada are
continually improving their delivery devices so that administration is easier,
enabling people with arthritis to think less about the treatment, and more
about getting on with their lives," says John Fleming, President and CEO of
The Arthritis Society.
ABOUT ENBREL SURECLICK(TM) AUTOINJECTOR
With ENBREL SureClick autoinjector, ENBREL is now available in three
administration options, including the 50 mg/mL prefilled syringe, 25 mg
multiple use vial and now ENBREL SureClick autoinjector. ENBREL has more than
14 years of worldwide clinical experience, and has been used in more than
450,000 patients worldwide. To date ENBREL has more than 1,000,000
patient-years of experience.(1)
HOW ENBREL WORKS
In patients with rheumatoid arthritis, juvenile rheumatoid arthritis,
psoriatic arthritis, psoriasis, and ankylosing spondylitis, ENBREL works by
inactivating tumor necrosis factor (TNF), one of the immune system messengers
that promotes joint and skin inflammation.(2) By reducing the amount of TNF in
your body, and bringing it back to normal levels, ENBREL can help treat joint
damage and skin patches (psoriatic skin lesions).(3)
ABOUT RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a chronic, progressive and disabling disease,
affecting approximately one out of every hundred Canadians.(4) The disease
commonly develops in early adulthood and affects three times as many women as
men.(5) Rheumatoid arthritis is a destructive type of arthritis, and in many
cases, can progress rapidly. Rheumatoid arthritis can affect any joint, most
commonly affecting the hands and feet.(6) Severe damage can lead to permanent
joint deformity and disability.(7) Research shows that for people affected by
rheumatoid arthritis, joint progression and damage occurred most often in the
hands, wrists and knees.(8)
Early diagnosis and aggressive treatment of rheumatoid arthritis is
critical to avoid the possibility of permanent disability and deformity.(9)
Recent evidence suggests that early and aggressive intervention and treatment
with a biologic can actually halt disease progression in many people.(10) It
is important for patients with symptoms of rheumatoid arthritis to consult a
physician for a definitive diagnosis.
In addition to the painful physical symptoms of rheumatoid arthritis, many
people experience feelings of helplessness and depression.(11) Being active,
seeking information and thinking rationally all seem to help patients adapt to
the emotional stresses of the disease.(12)
Psoriasis tends to run in families(13) and can strike at any age.(14)
Psoriasis triggers include: emotional stress, injury to the skin, some types
of infection and reaction to certain drugs. Plaque psoriasis is the most
common form of the disease, with red skin lesions covered by silvery scales
which come loose and shed continually.
Studies show that patients with psoriasis reported a reduction in physical
and mental functioning comparable to that seen in cancer, arthritis,
hypertension, heart disease, diabetes and depression.(15) It is estimated that
psoriasis costs the Canadian economy approximately $1.3 billion a year.(16)
AMGEN CANADA AND WYETH CANADA
Amgen Canada and Wyeth Canada market ENBREL in Canada. Immunex
Corporation, a wholly owned subsidiary of Amgen, manufactures ENBREL.
Additional information about ENBREL, including full Prescribing Information,
can be found by calling toll free 1-877-9ENBREL (1-877-936-2735).
Amgen discovers, develops and delivers innovative human therapeutics. A
biotechnology pioneer since 1980, Amgen was one of the first companies to
realize the new science's promise by bringing safe, effective medicines from
lab, to manufacturing plant, to patient. Amgen therapeutics have changed the
practice of medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis, and other serious
illnesses. With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve people's lives.
To learn more about Amgen's pioneering science and our vital medicines, visit
Wyeth (NYSE: WYE) is one of the world's largest research-driven
pharmaceutical and health care products companies. It is a leader in the
discovery, development, manufacturing and marketing of pharmaceuticals,
vaccines, biotechnology products and non-prescription medicines that improve
the quality of life for people worldwide.
Wyeth Canada (www.wyeth.ca), an affiliate of Wyeth, employs over
1,700 people across the country with a commercial head office in Markham,
Ontario and manufacturing and R&D facilities in Montréal, Québec. It markets
leading products in the areas of women's health care, neuroscience,
musculoskeletal therapy, transplantation and immunology, hemophilia and
(1) Amgen, Wyeth data on file.
(2) ENBREL Product Monograph, September 1, 2006. p. 25
(4) Arthritis Society of Canada
Accessed November 22, 2006.
(5) Arthritis Society of Canada.
asp?s=1. Accessed October 20, 2006.
(6) Arthritis Society of Canada
(8) Scott DL, et al. Long term progression of joint damage in rheumatoid
arthritis. Annals of the Rheumatic Diseases, 1986, Vol 45, 373-378.
(9) Arthritis Society of Canada
(10) Moreland LW, et al. Treatment of rheumatoid arthritis with a
recombinant human tumor necrosis factor receptor (p75)-Fc fusion
protein. N Rngl J Mrf 1997, 337:141-147.
(11) Arthritis Society of Canada.
asp?s=1. Accessed February 19, 2007.
(13) Elder JT et al. The genetics of psoriasis 2001: the odyssey
continues. Arch Dermatol. 2001 Nov; 137 (11):1447-54.
(14) Canadian Dermatology Association, Understanding Psoriasis
(15) Rapp SR et al. Psoriasis Causes as Much Disability as other Major
Medical Diseases, J Am Acad Dermatol. 1999 Sep;41 (3 pt 1):401-7.
(16) Piwko C et al. Economic Burden of Moderate to Severe Chronic Plaque
Psoriasis in Canada. Presented at the Canadian Association for
Population Therapeutics Annual Meeting, Vancouver, BC, April 2005.
For further information:
For further information: please contact: Julie Seidel, Edelman, (514)
844-6665, ext. 244, Julie.Seidel@edelman.com